Scholarlink

Purpose <p>The role of local cranial radiation (LCR) combined with third-generation tyrosine kinase inhibitors (TKIs) in the following the progression to leptomeningeal metastasis (LM) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastasis (BM) remains unclear. This study investigates whether LCR combined with third-generation TKIs can influence the occurrence LM in EGFR-mutated NSCLC with BM.</p> Methods <p>Patients diagnosed with EGFR exon 19del or exon 21 L858R mutant NSCLC with LM in Guangdong Sanjiu Brain Hospital were recruited into the study between January 1, 2018 and December 31, 2023. They were separated into two groups according to whether they received LCR during the period from BM to LM on not. The primary endpoints were the LM disease-free survival (LM-DFS) and LM rate.</p> Results <p>A total of 93 patients were enrolled, 60 in the TKIs group and 33 in the LCR + TKIs group. The median LM-DFS of the TKIs group and the LCR + TKIs group were 14.1 months (95% CI 12.3–19.8 months) and 27.0 months (95% CI 19.4–35.1 months), respectively (<i>p</i> &lt; 0.01). After propensity score matching, the median LM-DFS were 13.2 months (95% CI 9.5–21.6 months) and 24.6 months (95% CI 18.1–35.1 months), respectively (<i>p</i> = 0.01). 2-year LM rates in TKIs group and LCR + TKIs group were 78.3% and 45.5% in all patients (<i>p</i> &lt; 0.01); 76.9% and 50.0% in matched cohort (<i>p</i> = 0.02), respectively.</p> Conclusion <p>LCR combined with third-generation TKIs could improve LM-DFS and decrease 2-year LM rate compared with third-generation TKIs alone. Further studies are required to ascertain this effect.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月18日

查看全文
  • Qian Wang,
  • Hui Wang,
  • Weiping Hong,
  • Shoaib Bashir,
  • Xiaoyu Hua,
  • Yanying Yang,
  • Junjie Zhen,
  • Juan Li,
  • Mingyao Lai,
  • Linbo Cai

摘要

Purpose

The role of local cranial radiation (LCR) combined with third-generation tyrosine kinase inhibitors (TKIs) in the following the progression to leptomeningeal metastasis (LM) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastasis (BM) remains unclear. This study investigates whether LCR combined with third-generation TKIs can influence the occurrence LM in EGFR-mutated NSCLC with BM.

Methods

Patients diagnosed with EGFR exon 19del or exon 21 L858R mutant NSCLC with LM in Guangdong Sanjiu Brain Hospital were recruited into the study between January 1, 2018 and December 31, 2023. They were separated into two groups according to whether they received LCR during the period from BM to LM on not. The primary endpoints were the LM disease-free survival (LM-DFS) and LM rate.

Results

A total of 93 patients were enrolled, 60 in the TKIs group and 33 in the LCR + TKIs group. The median LM-DFS of the TKIs group and the LCR + TKIs group were 14.1 months (95% CI 12.3–19.8 months) and 27.0 months (95% CI 19.4–35.1 months), respectively (p < 0.01). After propensity score matching, the median LM-DFS were 13.2 months (95% CI 9.5–21.6 months) and 24.6 months (95% CI 18.1–35.1 months), respectively (p = 0.01). 2-year LM rates in TKIs group and LCR + TKIs group were 78.3% and 45.5% in all patients (p < 0.01); 76.9% and 50.0% in matched cohort (p = 0.02), respectively.

Conclusion

LCR combined with third-generation TKIs could improve LM-DFS and decrease 2-year LM rate compared with third-generation TKIs alone. Further studies are required to ascertain this effect.